Cannabis, marijuana and Hemp stock news from Investorideas.com plus daily cannabis #potcasts - Investor Ideas #Potcasts #Cannabis News and Stocks on the Move
Tuesday, November 21, 2017
Investorideas.com - The Path to New Drug Discoveries and Development with #Cannabis
Investorideas.com - The Path to New Drug Discoveries and Development with #Cannabis
Stocks Mentioned: Veritas Pharma Inc. (CSE: $VRT.C;
OTC: $VRTHF), Zynerba (NASDAQ: $ZYNE), GW Pharmaceuticals
(NASDAQ: $GWPH), Tetra Bio-Pharma (TSXV:
$TBP.V; $TBPMF), Aphria Inc (TSX: $APH.TO;
$APHQF)
OTC: $VRTHF), Zynerba (NASDAQ: $ZYNE), GW Pharmaceuticals
(NASDAQ: $GWPH), Tetra Bio-Pharma (TSXV:
$TBP.V; $TBPMF), Aphria Inc (TSX: $APH.TO;
$APHQF)
Point Roberts, WA, November 21, 2017 –
Investorideas.com, a global news source and investor resource covering cannabis
and hemp stocks issues a sector news alert on companies with new drug
discoveries and developments in the sector.
Investorideas.com, a global news source and investor resource covering cannabis
and hemp stocks issues a sector news alert on companies with new drug
discoveries and developments in the sector.
Investorideas.com - #Cannabis Stock News; Veritas' (CSE: $VRT.C) (OTC: $VRTHF) Research Division to Begin Human Trials of Its Lead #Cannabis Strain for Pain; @VeritasPharma
Investorideas.com - #Cannabis Stock News; Veritas' (CSE: $VRT.C) (OTC: $VRTHF) Research Division to Begin Human Trials of Its Lead #Cannabis Strain for Pain; @VeritasPharma
Research
Arm Cannevert Therapeutics Signs LOI with Fundación de Investigación of Puerto
Rico
Arm Cannevert Therapeutics Signs LOI with Fundación de Investigación of Puerto
Rico
Vancouver, B.C. - November 21, 2017
(Investorideas.com Newswire) Veritas Pharma Inc.- Cannabis and Biopharma News
alert - (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), ("Veritas" or the
"Company") reports that its research arm, Cannevert
Therapeutics Ltd. ("CTL") has signed a letter of intent with the
Fundación de Investigación (FDI) in San Juan, Puerto Rico, to conduct the first
human study of CTL-X, its lead cannabis strain targeting pain.
(Investorideas.com Newswire) Veritas Pharma Inc.- Cannabis and Biopharma News
alert - (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), ("Veritas" or the
"Company") reports that its research arm, Cannevert
Therapeutics Ltd. ("CTL") has signed a letter of intent with the
Fundación de Investigación (FDI) in San Juan, Puerto Rico, to conduct the first
human study of CTL-X, its lead cannabis strain targeting pain.
Monday, November 20, 2017
Investorideas.com - AgriTech Company Sells to Organic and Cannabis Markets
Investorideas.com - AgriTech Company Sells to Organic and Cannabis Markets
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Investorideas.com - The Lowdown on Getting High in Canada
Investorideas.com - The Lowdown on Getting High in Canada
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Investorideas.com - Veritas' (CSE: $VRT.C) (OTC: $VRTHF) Research Arm Cannevert Therapeutics Signs LOI with Fundación de Investigación of Puerto Rico to Begin Human Trials of Its Lead #Cannabis Strain for Pain
Investorideas.com - Veritas' (CSE: $VRT.C) (OTC: $VRTHF) Research Arm Cannevert Therapeutics Signs LOI with Fundación de Investigación of Puerto Rico to Begin Human Trials of Its Lead #Cannabis Strain for Pain
Veritas
Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt:
2VP), (“Veritas” or the “Company”) announces that its research arm, Cannevert
Therapeutics Ltd. ("CTL") has signed a letter of intent with the
Fundación de Investigación (FDI) in San Juan, Puerto Rico, to conduct the first
human study of CTL-X, its lead cannabis strain targeting pain.
Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt:
2VP), (“Veritas” or the “Company”) announces that its research arm, Cannevert
Therapeutics Ltd. ("CTL") has signed a letter of intent with the
Fundación de Investigación (FDI) in San Juan, Puerto Rico, to conduct the first
human study of CTL-X, its lead cannabis strain targeting pain.
The
study will be done in two stages to assess the analgesic effects of this lead
strain. The first stage will have an open label design to look at the feasibility
of two doses of CTL-X in 5 subjects while the second stage will use a
randomized, double-blind, crossover design to assess one dose of CTL-X against
a placebo control strain in 16 subjects who will be exposed to various
modalities of acute pain.
study will be done in two stages to assess the analgesic effects of this lead
strain. The first stage will have an open label design to look at the feasibility
of two doses of CTL-X in 5 subjects while the second stage will use a
randomized, double-blind, crossover design to assess one dose of CTL-X against
a placebo control strain in 16 subjects who will be exposed to various
modalities of acute pain.
Subscribe to:
Posts (Atom)